eXoZymes (EXOZ) AI Stock Analysis

• Market Cap: N/A
• Dividend Yield: N/A
• Average Volume (3M): 10.47K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.25
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 31
• Sector: Technology
• Sector Strength: 81
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 8,367,810
• 10 Day Avg. Volume: 1,614
• 30 Day Avg. Volume: 10,473
• PEG Ratio: -0.73
• Price to Book (P/B): -182.93
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -47.84
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: -4.00
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 35 Underperform
• Price Target: ―

eXoZymes' financial performance is the primary concern due to zero revenue generation and continuous operational losses. The technical analysis also points to a bearish trend, with the stock trading below key moving averages. The valuation remains difficult to assess without traditional metrics. These factors contribute to a low overall stock score, indicating significant risk.

eXoZymes Business Overview & Revenue Model

Company Description

eXoZymes (EXOZ) is a biotechnology company focused on the development and commercialization of enzyme-based solutions for various industrial applications. Operating within the biotechnology and environmental sectors, eXoZymes leverages advanced enzyme engineering to create sustainable and efficient processes for industries such as agriculture, waste management, and biofuels. The company's core products are customized enzymes that enhance productivity and reduce environmental impact.

How the Company Makes Money

eXoZymes generates revenue through the sale of its enzyme products to industrial clients seeking to improve their processes' efficiency and sustainability. The company operates on a B2B model, offering tailored enzyme solutions that cater to specific industrial needs. Key revenue streams include direct sales of enzyme formulations, licensing agreements for proprietary enzyme technology, and strategic partnerships with industrial enterprises aiming to integrate eco-friendly solutions into their operations. Additionally, eXoZymes may engage in research collaborations with academic institutions, receiving funding to further develop its enzyme technologies, which can contribute to its earnings.

eXoZymes Financial Statement Overview

Summary

eXoZymes faces substantial financial hurdles, primarily due to zero revenue generation and persistent operational losses. While the balance sheet shows improved equity, the reliance on external financing and negative cash flows highlight sustainability concerns. The company needs to address its revenue generation and operational efficiency to improve its financial health.

Income Statement

eXoZymes has consistently reported zero revenue over the past years, indicating a lack of revenue generation capabilities. The company is operating at a loss with a negative EBIT and net income, reflecting significant operational challenges. The absence of revenue growth further underscores the financial struggles, posing a substantial risk to future profitability.

Balance Sheet

eXoZymes exhibits a relatively strong equity position with an improvement in stockholders' equity from negative to positive in the latest year. The debt-to-equity ratio indicates manageable leverage, but the lack of revenue generation raises concerns about future sustainability. The equity ratio reflects a strong equity base but is overshadowed by the absence of revenue.

Cash Flow

The company's operating cash flow is negative, indicating challenges in covering operational expenses. However, significant financing inflows have bolstered cash reserves, suggesting reliance on external funding. The free cash flow remains negative, emphasizing difficulties in generating cash for reinvestment and debt servicing.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement		Total Revenue
0.00	0.00	0.00	0.00
	Gross Profit
0.00	0.00	0.00	0.00
	EBIT
-5.93M	-1.80M	-1.33M	-1.29M
	EBITDA
-5.66M	-1.60M	-1.18M	-1.23M
	Net Income Common Stockholders
-5.86M	-2.04M	-1.40M	-1.21M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
9.72M	66.53K	558.57K	547.81K
	Total Assets
13.03M	3.56M	2.69M	2.35M
	Total Debt
1.39M	1.61M	608.77K	720.63K
	Net Debt
-8.33M	1.55M	50.20K	172.82K
	Total Liabilities
2.61M	3.94M	1.31M	1.15M
	Stockholders Equity
10.42M	-384.32K	1.37M	1.20M
Cash Flow		Free Cash Flow
-8.90M	-1.47M	-1.44M	-2.01M
	Operating Cash Flow
-8.51M	-1.18M	-1.26M	-1.59M
	Investing Cash Flow
-359.22K	-311.17K	-87.21K	-312.25K
	Financing Cash Flow
18.52M	1.00M	1.36M	2.31M

eXoZymes Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	62 Neutral	$11.92B	10.03	-7.37%	3.70%	7.32%	-8.25%
BDRX	45 Neutral	$695.34K	―	-89.21%	―	-83.72%	99.56%
GRI	45 Neutral	$3.19M	―	-468.00%	―	―	98.55%
EXOZ	35 Underperform		―		―	―	―
SLRX	30 Underperform	$2.23M	―	-300.16%	―	―	79.57%
PCSA	29 Underperform	$2.68M	―	-192.72%	―	―	56.26%
PTIX	27 Underperform	$2.94M	―	-512.79%	―	―	-40.51%

eXoZymes Corporate Events

eXoZymes Announces Leadership Changes with New Appointments

On February 17, 2025, eXoZymes Inc., a Nevada corporation, experienced significant leadership changes as Mr. Mohammad Hayat resigned from his roles as President, Chairman, and Board member. Subsequently, the Board appointed Mr. Edgardo Rayo as a new Board member and Mr. Christopher A. Marlett as the new Chairman.